摘要
肺癌是临床上最常见的恶性肿瘤之一,尚缺乏预后较为理想的治疗方案。肿瘤干细胞学说认为肺癌干细胞是肺癌发生、发展、转移、复发、耐受放化疗以及肺癌细胞具有侵袭性的主要原因。近年来越来越多的机构利用CD133糖基化表位来鉴定、分离、提纯肺癌干细胞。然而,随着研究的深入,CD133作为肺癌干细胞标记物逐渐受到质疑。本文对近年来利用CD133作为肺癌干细胞表面标记物的应用及其局限性做一综述。
Lung cancer is one of the most common tumor, which lacks of effective clinical treatment to lead to desirable prognosis. According to cancer stem cell hypothesis, lung cancer stem cells are considered to be responsible for carcinogenesis, development, metastasis, recurrence, invasion, resistance to chemotherapy and radiotherapy of lung cancer. In recent years, more and more institutes used glycosylated CD133 epitopes to define, isolate, purify lung cancer stem cells. However, along with deeply research, the application of CD133 epitopes in lung cancer stem cell research is questioned. The utilization and limitation of CD133 epitopes in lung cancer stem cells research for the past few years is summaried in this review.
出处
《中国肺癌杂志》
CAS
2011年第10期825-829,共5页
Chinese Journal of Lung Cancer
